Similar articles

• Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes.

  Imasawa M, Tsumura T, Sekine A, Kikuchi T, Iijima H. Imasawa M, et al. Jpn J Ophthalmol. 2009 Nov;53(6):588-592. doi: 10.1007/s10384-009-0732-1. Epub 2009 Dec 18. Jpn J Ophthalmol. 2009. PMID: 20020236
• Central retinal sensitivity measured with the micro perimeter 1 after photodynamic therapy for polypoidal choroidal vasculopathy.

  Yodoi Y, Tsujikawa A, Kameda T, Otani A, Tamura H, Mandai M, Yoshimura N. Yodoi Y, et al. Am J Ophthalmol. 2007 Jun;143(6):984-994. doi: 10.1016/j.ajo.2007.01.026. Epub 2007 Mar 6. Am J Ophthalmol. 2007. PMID: 17336913
• Reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

  Chhablani J. Chhablani J. Am J Ophthalmol. 2010 Sep;150(3):443-4; author reply 444. doi: 10.1016/j.ajo.2010.05.033. Am J Ophthalmol. 2010. PMID: 20728684 No abstract available.
• Preserving vision with verteporfin photodynamic therapy.

  Yang YC. Yang YC. Hosp Med. 2004 Jan;65(1):39-43. doi: 10.12968/hosp.2004.65.1.2417. Hosp Med. 2004. PMID: 14964795 Review.
• Photodynamic therapy: current role in the treatment of chorioretinal conditions.

  Newman DK. Newman DK. Eye (Lond). 2016 Feb;30(2):202-10. doi: 10.1038/eye.2015.251. Epub 2016 Jan 8. Eye (Lond). 2016. PMID: 26742867 Free PMC article. Review.